• About us
• Contact

Advertisement

Organisation › Details

Progenika Biopharma S.A.

Progenika Biopharma SA is a biotechnology company specialised in personalized medicine that develops DNA biochips for the diagnosis, prognosis and prediction of response to treatment human diseases. Progenika offers a series of tools for molecular diagnosis in areas such as: inmunohematology, familial hypercholesterolemia, nervous system disorders, and treatment optimization. In addition to BLOODchip, other leading products include LIPOchip, PHARMAchip, and Promonitor. Progenika was founded in 2000 and has development and production centres in Bizkaia Technology Park (Spain), Medford (Massachusetts, USA) and Mexico D.F. Its products are marketed in America, Europe and the Middle East. *

 

	Start	2000-04-01 established
	Group	Grifols (Group)
	Industry	DNA microarray technology
	Region	Spain_oo
	Country	Spain (España)
	Street	Parque Tecnológico de Bizkaia, Building 801B
	City	48160 Derio-Vizcaya
	Tel	+34-944-064-525
		Address record changed: 2020-12-02
Basic data	Employees	D: 101 to 500 (2010-09-28)
		* Document for »About Section«:
		Record changed: 2017-11-20

Advertisement

More documents for Grifols (Group)

• [1] Biotest AG. (4/25/22). "Press Release: Grifols Acquires Majority of Voting Rights in Biotest". Dreieich....
• [2] Grifols S.A.. (9/17/21). "Press Release: Grifols Acquires Tiancheng Pharmaceutical Holdings, the Largest Shareholder of Biotest, to Increase Patients’ Access to Plasma Therapies". Barcelona....
• [3] Grifols S.A.. (11/24/20). "Press Release: Strategic Alliance between Grifols and the Egyptian Government to Boost Plasma-derived Medicines Self-sufficiency in the Middle East and Africa". Barcelona....
• [4] Grifols S.A.. (9/7/20). "Press Release: Grifols to Acquire Alkahest to Enhance Discovery Research and Development". Barcelona & San Carlos, CA....
• [5] Grifols S.A.. (2/18/20). "Press Release: Grifols and the Public Investment Fund of Saudi Arabia Taking Steps to Boost Plasma Medicines Self-supply in the Region". Barcelona....
• [6] Grifols S.A.. (11/13/19). "Press Release: Grifols and Shanghai RAAS Obtain Authorization for Their Strategic Alliance in China". Barcelona....
• [7] Grifols S.A.. (7/31/19). "Press Release: Grifols Increases Its Revenues by 14.3% to EUR 2,423 million, Driven by Its Strategic Growth Plan". Barcelona....
• [8] Grifols S.A.. (2/7/19). "Press Release: Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System". Barcelona....
• [9] Grifols S.A.. (1/23/19). "Press Release: Grifols Announces Collaboration and License Agreement with Rigel Pharmaceuticals to Commercialize Fostamatinib in Europe". Barcelona....
• [10] European Invesmtent Bank (EIB). (9/7/18). "Press Release: Investment Plan for Europe – the EIB and Grifols Sign a New Loan Agreement to Advance Research on Rare and Chronic Diseases"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.